Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Immuron Limited ( (AU:IMC) ) is now available.
Immuron Limited reported a 34% year-over-year increase in global sales for Q1 FY26, driven by strong performance in Australia and the USA. The company’s flagship product, Travelan®, an immune supplement targeting gastrointestinal pathogens, saw significant growth due to enhanced marketing efforts and increased travel activity. While Canadian sales were down, Immuron anticipates recovery through upcoming consumer promotions and increased brand awareness.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
YTD Price Performance: 12.66%
Average Trading Volume: 253,021
Technical Sentiment Signal: Hold
Current Market Cap: A$23.87M
See more insights into IMC stock on TipRanks’ Stock Analysis page.